Biomonitor, part of Euro Diagnostica, will launch new cell based assays – IL-23 and TNFα - for biotherapeutics at the PEGS Boston, May 4-8 2015.

April 22, 2015 - Company News, Product News, Disease Area News
New assays for functional measurement of IL-23 and anti-TNF-alpha will be launched at the PEGS summit. They are all based on the unique iLite™ reporter gene technology. Data will be shared at the poster session and at the Biomonitor booth #440.

Come and learn about the iLite™ technology

Dr. Michael G. Tovey, Ph.D., Managing Director, Biomonitor SAS, France, will also be presenting the new data under the title: “iLite™ Reporter Gene Technology: Assay Sensitivity & Specificity throughout the Drug Development Life Cycle” Thursday, May 7, 3.20 pm, Cityview Ballroom 2.

Please join us and learn how Biomonitor can help you in your small or large drug discovery programme!

Read more about iLite™.

About Biomonitor

Biomonitor supports pharma and biotech companies in the development of biopharmaceuticals, from early discovery to clinical phases with; assay-ready frozen reporter gene cells;, specialized CRO services, customized reporter gene cell-based assay development and patient monitoring services. 

« Back